86 related articles for article (PubMed ID: 12404281)
1. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors.
Miki T; Mizutani Y; Nonomura N; Nomoto T; Nakao M; Saiki S; Kotake T; Okuyama A
Cancer; 2002 Nov; 95(9):1879-85. PubMed ID: 12404281
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Nishikawa M; Miyake H; Fujisawa M
Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313
[TBL] [Abstract][Full Text] [Related]
4. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
Nomoto T; Mizutani Y; Mikami K; Nakamura T; Nakanishi H; Kawauchi A; Miki T
Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):630-5. PubMed ID: 16768143
[TBL] [Abstract][Full Text] [Related]
5. [The salvage chemotherapy for refractory testicular cancer with novel anticancer agents].
Miki T; Nomoto T; Nakagawa S; Nakao M; Nonomura N; Takada T; Saiki S; Kotake T
Hinyokika Kiyo; 1999 Nov; 45(11):811-4. PubMed ID: 10637749
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS
Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464
[TBL] [Abstract][Full Text] [Related]
8. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Choi HJ; Cho BC; Shin SJ; Cheon SH; Jung JY; Chang J; Kim SK; Sohn JH; Kim JH
Cancer Chemother Pharmacol; 2008 Feb; 61(2):309-13. PubMed ID: 17576560
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.
Xiao H; Mazumdar M; Bajorin DF; Sarosdy M; Vlamis V; Spicer J; Ferrara J; Bosl GJ; Motzer RJ
J Clin Oncol; 1997 Jul; 15(7):2553-8. PubMed ID: 9215824
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
Kang HJ; Kim WS; Suh C; Park YH; Kim BS; Yuh YJ; Ryoo BY
Cancer Chemother Pharmacol; 2008 Jul; 62(2):299-304. PubMed ID: 17922274
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Ilson DH
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of irinotecan combined with cisplatin by divided administration in patients with untreated primary non-small cell lung cancer].
Asano T; Namikawa O; Yamamoto A; Sano T; Mukai J; Kawaji K; Kobayashi M
Nihon Kokyuki Gakkai Zasshi; 1998 Sep; 36(9):771-5. PubMed ID: 9866979
[TBL] [Abstract][Full Text] [Related]
14. [Two cases of relapse or refractory germ cell tumor who had been treated with combination chemotherapy of cisplatin and carboplatin].
Kiyama Y; Suzuki G; Masauzi N; Ohizumi H; Kobayashi N; Ogasawara M; Naohara T; Saito M; Higa T; Kasai M
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1989-92. PubMed ID: 8978809
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
Takiguchi Y; Moriya T; Asaka-Amano Y; Kawashima T; Kurosu K; Tada Y; Nagao K; Kuriyama T
Lung Cancer; 2007 Nov; 58(2):253-9. PubMed ID: 17658654
[TBL] [Abstract][Full Text] [Related]
17. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).
Theodore C; Skoneczna I; Bodrogi I; Leahy M; Kerst JM; Collette L; Ven K; Marréaud S; Oliver RDT;
Ann Oncol; 2008 Jul; 19(7):1304-1307. PubMed ID: 18417462
[TBL] [Abstract][Full Text] [Related]
18. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
19. [A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage
treatment in refractory or relapsed small cell lung cancer].
Yu S; Wang Y; Hu X; Wang H; Hao X; Xu J; Li J; Zhang X; Shi Y
Zhongguo Fei Ai Za Zhi; 2013 Sep; 16(9):470-5. PubMed ID: 24034994
[TBL] [Abstract][Full Text] [Related]
20. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
